Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Abstract

Glofitamab therapy was effective for DLBCL. More than half the patients had an adverse event of grade 3 or 4. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT03075696.).